Cancer-Focused Cellectar Biosciences Stock Trades Lower Despite Meeting Goal In Blood Cancer Study
Portfolio Pulse from Vandana Singh
Cellectar Biosciences Inc. (NASDAQ:CLRB) stock is trading lower despite meeting the primary endpoint in its CLOVER WaM pivotal study for relapsed/refractory Waldenstrom’s macroglobulinemia. The study showed an overall response rate of 80% and a major response rate of 56.4%, exceeding the primary endpoint of 20% MRR. The company plans to file an FDA marketing application in Q4 2024.
July 23, 2024 | 2:49 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cellectar Biosciences Inc. (NASDAQ:CLRB) stock is down 24.83% despite positive results from its CLOVER WaM study for relapsed/refractory Waldenstrom’s macroglobulinemia. The study exceeded its primary endpoint, showing an ORR of 80% and MRR of 56.4%. The company plans to file an FDA marketing application in Q4 2024.
Despite the positive clinical results, the stock price dropped significantly, likely due to market expectations or other external factors. The upcoming FDA application in Q4 2024 could be a future catalyst.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100